Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Acorda, Watson partner to introduce generic zanaflex capsules

PBR Staff Writer Published 07 February 2012

Acorda Therapeutics and Watson Pharma, a subsidiary of Watson Pharmaceuticals, have collaborated to introduce tizanidine hydrochloride capsules, an authorized generic version of zanaflex capsules (tizanidine hydrochloride).

Acorda will receive a royalty from Watson based on product sales.

Additional terms of the agreement have not been disclosed.

Tizanidine hydrochloride capsule is a short-acting drug indicated for the management of spasticity.

Because of the short duration of effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important, Acorda said.

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.